| Description |
Recombinant Mouse Kallikrein 5/KLK5 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gly30-Asn293. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q9D140 |
| Target Symbol |
Kallikrein 5/KLK5 |
| Synonyms |
Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Gly30-Asn293 |
| Mol. Weight |
The protein has a predicted MW of 29.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in 20mM NaAc, 150mM NaCl (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
